Tenzing and Reviva Pharmaceuticals announced in a filing that Narayan Prabhu has been recruited to join the combined public company as CFO, following completion of the merger. A shareholder vote is set for Dec. 8 on the proposed merger with Reviva, a California-based clinical stage pharmaceutical company. If approved, the combined companies would have a valuation of $119M. Read more.
Related Posts
Digital Health Files Proxy on $110M VSee & iDoc Deals
VSee Lab is a telehealth software company, and iDoc Telehealth is a neurocritical care and intensive care telehealth provider.
BlueRiver Hit with Delisting Notice, Extends Termination Date on Spinal Stablization Technologies Deal
At deal announcement last July, the combined company was expected to have an estimated post-transaction enterprise value of approximately $302 million.
Graf Acquisition IV Announces 4th Adjournment of NKGen Biotech Merger Vote
NKGen has now waived the $50 million minimum cash condition to seal the deal.
PMV Consumer Acquisition Redeeming Stock, But Won’t Liquidate Just Yet
The SPAC thereafter expects to continue to pursue a wide range of business opportunities operating as a blank check shell company with its Class A Common Stock quoted on the OTC Pink market.